Mechanistically, we show this prosurvival phenotype is driven by enhanced JAK/STAT and identify BIRC5 as a specific genetic dependency and therapeutic vulnerability of DNMT3A-mutant T-ALL cells. This evidence concerns the gene DNMT3A and acute lymphoblastic leukemia.